Liquid Biopsy for the Diagnosis of Intestinal-type Adenocarcinoma of the Ethmoid (BLADE)

Launched by UNIVERSITY HOSPITAL, MONTPELLIER · Oct 18, 2023

Keywords

ClinConnect Summary

The BLADE trial is a study aimed at understanding how well a new test called liquid biopsy can detect a specific type of cancer called intestinal-type adenocarcinoma of the ethmoid, which is a tumor located in the sinus area of the face. This test involves taking a blood sample from participants during surgery or when their cancer is diagnosed again. The researchers will compare results from two different groups: one group will be matched by age and gender, while the other will be matched based on exposure to certain substances, like wood dust or nickel, which can increase cancer risk.

To participate in this trial, you need to be at least 18 years old and have a diagnosis of adenocarcinoma of the ethmoid. There are also control groups for those without this type of cancer but who fit specific criteria. If you join the study, you can expect to provide blood samples at various times after your surgery to help researchers learn more about this cancer and improve future diagnosis methods. It’s important to know that the trial is not yet recruiting participants, so there will be further announcements about when it will start.

Gender

ALL

Eligibility criteria

• Inclusion Criteria:
• • Case group: diagnosis of adenocarcinoma of the ethmoid on biopsy or imaging recurence; age\>/= 18 years; patient consent ;
• • Age and gender-matched control group: consulting patient in otolaryngology head and neck surgery department without adenocarcinoma of the ethmoid; no personal history of cancer; no familial history of colorectal adenocarcinoma;
• • Exposition control group: Professional exposition to wood dust, leaver or nickel for at least 12 months; consulting patient in otolaryngology head and neck surgery department without adenocarcinoma of the ethmoid; no personal history of cancer; no familial history of colorectal adenocarcinoma;
• Exclusion Criteria:
• • patient presenting with another malignant tumor
• • deprivation of liberty
• • patient under guardianship
• • Other cancer diagnosed or under treatment
• • Recurrent patient previously included in the study
• • Refusal to accept the monitoring described and/or to provide the information required for the study
• • No affiliation or non-beneficiary of a Social Security system;
• • Pregnant or breast-feeding women in accordance with article L1121-5 of the Public Health Code (CSP)